Dieters Fail Because Of Hormones Not Lack Of Will Power

Thursday, October 27th, 2011

New research released tomorrow in the New England Journal of Medicine, suggests that people fail to lose weight on diets, more because of hormone imbalances than lack of will power. The crux of the problem is that as a person loses weight, especially in more aggressive dieting, the body ...

Moving Poor Women To Less Impoverished Neighborhoods Improves Their Health

Thursday, October 20th, 2011

A study by researchers from the University of Chicago has shown that 'location location' as real estate agents are fond of saying, can also work for improving health. Low income women with children who moved to better neighborhoods showed better health statistics, including reductions in diabetes and obesity. The ...

Experimental Malaria Vaccine Cuts Malaria Risk By Half In Very Young Children

Wednesday, October 19th, 2011

Preliminary results of Phase 3 clinical trial, which is still underway, on RTS,S, an experimental malaria vaccine, showed that it reduces malaria risk in babies aged 5 to 17 months by half. The results have been published in NEJM (New England Journal of Medicine. Malaria kills nearly 800,000 people annually, ...

Relapses Reduced In Multiple Sclerosis Patients By New Oral Drug

Monday, October 10th, 2011

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the drug teriflunomide were published in The New England Journal ...

Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate AndDisability Progression

Saturday, October 8th, 2011

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM). Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability ...